Are increased levels of von Willebrand factor in chronic coronary heart disease caused by decrease in von Willebrand factor cleaving protease activity? A study by an immunoassay with antibody against intact bond 842Tyr-843Met of the von Willebrand factor protein
S. He et al., Are increased levels of von Willebrand factor in chronic coronary heart disease caused by decrease in von Willebrand factor cleaving protease activity? A study by an immunoassay with antibody against intact bond 842Tyr-843Met of the von Willebrand factor protein, THROMB RES, 103(3), 2001, pp. 241-248
Low levels of von Willebrand factor (VWF) in von Willebrand's disease type
2A (VWD 2A) result from increased cleavage of the bond 842Tyr-843Met in the
VWF protein by VWF cleaving protease. On the other hand, decreased levels
of this protease result in unusually large VWF in thrombotic thrombcytopeni
c purpura with thrombotic complications. In the present study, we designed
an enzyme-liked immunosorbent assay of VWF cleaving protease activity to be
used to assess whether the high levels of VWF in coronary heart disease (C
HID) relate to a deficiency of this protease. Plasma samples with added Pef
abloc and CaCl2 were incubated with purified VWF coated on a microtiter pla
te. The remaining undigested multimers were quantified by an antibody direc
ted against the intact 842Tyr-843Met bond of the VWF protein. Phosphate-buf
fered saline (PBS), instead of plasma, was used to obtain the initial level
of coated undigested VWF. The reduction in absorbance at 492 run between P
BS and the unknown sample was taken as a measure of the protease activity.
The assay was applied to plasma samples from 21 senior women with chronic C
HID (cases) and 34 age-matched controls, as well as to samples from three p
atients with VWD 2A. The protease activity was similar in the two women gro
ups (P > .05), although the VWF antigen levels were higher in the cases (P
< .01). The VWD 2A patients had similar plasma levels of the protease to th
at in normal pooled plasma (NPP). In the senior controls, the protease acti
vity correlated with the subject age (r's = -.61, P < .01, n = 34). In conc
lusion, the developed method is specific for evaluating the protease functi
on on VWF cleavage. The moderate increase of VWF antigen in chronic CHD may
not depend on the protease activity. The age influence on the protease lev
els supports earlier findings of higher VWF levels in healthy older subject
s. A high sensitivity of the mutated protein of VWF for the protease effect
rather than increases in activity or quantity of the enzyme is probably in
volved in the pathogenesis of VWD 2A. (C) 2001 Elsevier Science Ltd. All ri
ghts reserved.